Drug intelligence / Profile preview

cell-free supernatant of Clostridium leptum

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

Cell-free supernatant of Clostridium leptum (ClCFS) is an experimental biologic therapeutic being investigated for its anti-cancer properties, particularly in breast cancer. [1, 2] It is a complex mixture containing metabolites and soluble factors produced by *Clostridium leptum*, a butyrate-producing anaerobic bacterium that is part of the healthy human gut microbiota. [1, 10] Research suggests that ClCFS inhibits the proliferation of breast cancer cells by inducing apoptosis (programmed cell death). [1, 2] Untargeted metabolomics has identified acetylcarnitine as a potentially key bioactive metabolite. [2] Network pharmacological analysis predicted that its anti-cancer effects may be mediated through core targets including STAT3, IL-1β, BCL2, CASP3, and ESR1. [2] The product is in the preclinical stage of research, and no specific developing company or brand name has been identified. [2]

Targets

BCL-2 (BCL-2 family)STAT3 (Signal Transducer and Activator of Transcription 3)CASP3 (Caspase-3)ESR1 (ERα)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on cell-free supernatant of Clostridium leptum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cell-free supernatant of Clostridium leptum.

Explore the full profile